Блог – PharmCAT.NET

PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Найти:

Свежие записи

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

ICH M12 Drug-Drug Interaction Studies Final Guidance - 10/09/2024
Source: FDA - What's New: Drugs RSS Feed Published on 2024-10-10 By FDA
Generic Drug Research Collaboration Opportunities
Source: FDA - What's New: Drugs RSS Feed Published on 2024-10-10 By FDA
Human medicines European public assessment report (EPAR): Dynastat, parecoxib, Date of authorisation: 22/03/2002, Revision: 38, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-10-10
First Generic Drug Approvals
Source: FDA - What's New: Drugs RSS Feed Published on 2024-10-10 By FDA
Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 6, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-10-10
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 6, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-10-10
Human medicines European public assessment report (EPAR): Spevigo, spesolimab, Date of authorisation: 09/12/2022, Revision: 1, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-10-10
Human medicines European public assessment report (EPAR): Tresiba, insulin degludec, Date of authorisation: 20/01/2013, Revision: 18, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-10-10
Human medicines European public assessment report (EPAR): Tukysa, tucatinib, Date of authorisation: 11/02/2021, Revision: 8, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-10-10
Human medicines European public assessment report (EPAR): Holoclar, ex vivo expanded autologous human corneal epithelial cells containing stem cells, Date of authorisation: 17/02/2015, Revision: 12, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-10-10
Patent Certifications and Suitability Petitions
Source: FDA - What's New: Drugs RSS Feed Published on 2024-10-09 By FDA
Generic Drug Facilities, Sites and Organization Lists
Source: FDA - What's New: Drugs RSS Feed Published on 2024-10-09 By FDA
The Drug Supply Chain Security Act (DSCSA) Waivers, Exceptions, and Exemptions
Source: FDA - What's New: Drugs RSS Feed Published on 2024-10-09 By FDA
Waivers and Exemptions Beyond the Stabilization Period
Source: FDA - What's New: Drugs RSS Feed Published on 2024-10-09 By FDA
Compounding when Drugs are on FDA’s Drug Shortages List
Source: FDA - What's New: Drugs RSS Feed Published on 2024-10-09 By FDA

Предыдущие записи

Тема: Scaffold от Danny Cooper.